A Phase 1a Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of OMP-336B11 Administered as a Single Agent to Subjects With Locally Advanced or Metastatic Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Jan 2019
At a glance
- Drugs OMP 336B11 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors OncoMed Pharmaceuticals
- 02 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 05 Dec 2018 According to an Oncomed media release, the company expects to complete enrolment in this trial before the end of 2018.
- 08 Mar 2018 According to an Oncomed media release, company is planning to present the data from this study in 2019.